PMID-33320179 – Revisiting the Complexity of GLP-1 Action
McLean BA, Wong CK, Campbell JE, et al. Revisiting the Complexity of GLP-1 Action-from Sites of Synthesis, to Receptor Activation, to Downstream Signaling. Endocrine Reviews, 2021;42(2):101-132.
Quick Reference
| Property | Value |
|---|---|
| PMID | 33320179 |
| DOI | 10.1210/endrev/bnaa032 |
| Year | 2021 |
| Journal | Endocrine Reviews |
| Study Type | Narrative Review |
| Evidence Level | V |
| Sample | N/A (comprehensive review) |
| Peptide(s) Studied | Semaglutide |
Key Findings
- GLP-1 is produced primarily by intestinal L-cells and brainstem neurons; both sources contribute to metabolic regulation through distinct but overlapping pathways
- GLP-1 receptor (GLP-1R) signaling involves cAMP-PKA, beta-arrestin, and biased agonism pathways, which may explain differential pharmacology among GLP-1 RAs
- Appetite suppression by GLP-1 RAs is mediated primarily through central GLP-1R activation in the hypothalamus and brainstem, with peripheral vagal afferent signaling playing a supporting role
- Cardiovascular benefits of GLP-1 RAs involve direct effects on cardiomyocytes, endothelial cells, and immune/inflammatory pathways, not solely mediated through weight loss or glycemic improvement
- Anti-inflammatory actions of GLP-1R activation include reduced NF-kB signaling, decreased macrophage infiltration, and attenuation of atherosclerotic plaque inflammation
- Gastric emptying deceleration is a significant contributor to postprandial glucose control but undergoes tachyphylaxis with sustained GLP-1 RA exposure
Study Design
Comprehensive narrative review synthesizing preclinical and clinical literature on GLP-1 biology, covering: biosynthesis and processing of proglucagon, sites of GLP-1 production, GLP-1 receptor structure and signaling cascades, physiological actions across organ systems (pancreas, brain, heart, GI tract, kidney, immune system), and pharmacological implications for GLP-1 RA development.
Limitations
- Narrative review without systematic search methodology or quality assessment of included studies
- Some mechanistic data derived from rodent models with uncertain human translatability
- Published before SELECT trial results; cardiovascular discussion does not include obesity-specific CV outcome data
- Does not cover dual/triple agonists (tirzepatide, retatrutide)
Clinical Relevance
This review serves as an essential mechanistic reference for understanding how semaglutide and other GLP-1 RAs exert their multi-organ effects. The discussion of biased agonism, central vs peripheral pathways, and anti-inflammatory mechanisms provides the scientific foundation for interpreting clinical trial results and understanding why GLP-1 RAs produce benefits beyond weight loss and glucose control.
Related
#research #narrative-review #semaglutide #evidence-level-V